MX2022000525A - Vacunas contra la ehrlichia y composiciones inmunogenicas. - Google Patents
Vacunas contra la ehrlichia y composiciones inmunogenicas.Info
- Publication number
- MX2022000525A MX2022000525A MX2022000525A MX2022000525A MX2022000525A MX 2022000525 A MX2022000525 A MX 2022000525A MX 2022000525 A MX2022000525 A MX 2022000525A MX 2022000525 A MX2022000525 A MX 2022000525A MX 2022000525 A MX2022000525 A MX 2022000525A
- Authority
- MX
- Mexico
- Prior art keywords
- immunogenic compositions
- vaccines against
- ehrlichia
- against ehrlichia
- adjuvant
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Gram-negative bacteria
- C07K16/1246—Rickettsiales (O)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/29—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Richettsiales (O)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0233—Rickettsiales, e.g. Anaplasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962873843P | 2019-07-12 | 2019-07-12 | |
| US201962879762P | 2019-07-29 | 2019-07-29 | |
| US202063049476P | 2020-07-08 | 2020-07-08 | |
| PCT/US2020/041779 WO2021011456A1 (en) | 2019-07-12 | 2020-07-13 | Ehrlichia vaccines and immunogenic compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022000525A true MX2022000525A (es) | 2022-04-20 |
Family
ID=71948757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022000525A MX2022000525A (es) | 2019-07-12 | 2020-07-13 | Vacunas contra la ehrlichia y composiciones inmunogenicas. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12624093B2 (enExample) |
| EP (1) | EP3996741A1 (enExample) |
| JP (1) | JP2022540197A (enExample) |
| CN (1) | CN114514238A (enExample) |
| AU (1) | AU2020314625A1 (enExample) |
| BR (1) | BR112022000347A2 (enExample) |
| CA (1) | CA3146842A1 (enExample) |
| CL (1) | CL2022000086A1 (enExample) |
| MX (1) | MX2022000525A (enExample) |
| PH (1) | PH12022550081A1 (enExample) |
| WO (1) | WO2021011456A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025118050A1 (pt) * | 2023-12-04 | 2025-06-12 | Laboratório Bio-Vet Ltda | Antígeno vacinal quimérico com ação tríplice contra erliquiose, anaplasmose e babesiose canina, vetor de expressão, célula recombinante, composição vacinal, kit de diagnóstico, método de tratamento e uso de proteína quimérica |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6043085A (en) * | 1998-08-27 | 2000-03-28 | Research Development Foundation | Ehrlichia canis 120-kDa immunodominant antigenic protein and gene |
| MXPA05004804A (es) | 2002-11-04 | 2005-12-05 | Res Dev Foundation | Antigenos de p153 y p156 para el inmunodiagnostico de erliquiosis canina y humana y usos de los mismos. |
| CA2555413C (en) | 2004-02-25 | 2013-12-17 | Research Development Foundation | An immunoreactive 38-kda ferric binding protein of ehrlichia canis and uses thereof |
| US20050202046A1 (en) | 2004-03-11 | 2005-09-15 | Wyeth | Canine vaccine for protection against ehrlichiosis |
| US7910593B2 (en) | 2004-04-09 | 2011-03-22 | Chugai Seiyaku Kabushiki Kaisha | Water-soluble prodrugs |
| US7842474B2 (en) * | 2005-04-04 | 2010-11-30 | Idexx Laboratories, Inc. | Ehrlichia canis DIVA (differentiate infected from vaccinated animals) |
| EP3527582B1 (en) * | 2005-04-04 | 2022-08-17 | IDEXX Laboratories, Inc. | Ehrlichia canis diva (differentiate infected from vaccinated animals) |
| US8591906B2 (en) * | 2005-06-16 | 2013-11-26 | Research Development Foundation | Immunoreactive protein orthologs of Ehrlichia canis and E. chaffeensis |
| EP1790656A1 (en) | 2005-11-25 | 2007-05-30 | Nanokem S.A. | Solution-phase synthesis of leuprolide |
| WO2008000070A1 (en) * | 2006-06-27 | 2008-01-03 | Wellington Laboratories Inc. | Glycyrrhetinic acid derivatives |
| EP2064231B2 (en) | 2006-08-31 | 2020-08-26 | Research Development Foundation | Immunoreactive glycoprotein gp19 of ehrlichia canis |
| CL2008001806A1 (es) | 2007-06-20 | 2008-09-05 | Wyeth Corp | Composicion de vacuna en emulsion agua en aceite que comprende un antigeno y un adyuvante en la fase acuosa; y metodo de elaboracion. |
| WO2009102509A2 (en) | 2008-01-10 | 2009-08-20 | Research Development Foundation | Vaccines and diagnostics for the ehrlichioses |
| ES2569907T3 (es) | 2008-06-27 | 2016-05-13 | Zoetis Services Llc | Composiciones adyuvantes novedosas |
| CA2796563C (en) | 2009-04-28 | 2018-05-22 | Research Development Foundation | Immunoreactive ehrlichia p120/p140 epitopes and uses thereof |
| HRP20181039T1 (hr) * | 2010-05-28 | 2018-08-24 | Zoetis Belgium S.A. | Cjepiva koja sadrže kolesterol i cpg kao jedine molekule koje nose adjuvans |
| EP2433646A1 (en) * | 2010-09-22 | 2012-03-28 | Intervet International BV | Vaccine against Ehrlichia canis and associated methods |
| CA2874966C (en) * | 2012-05-31 | 2020-06-09 | Zoetis Services Llc | Vaccination with canine respiratory coronavirus for protection against b. bronchiseptica infections |
| SI3542819T1 (sl) | 2013-05-14 | 2021-11-30 | Zoetis Services Llc | Sestave novih cepiv, ki vsebujejo imunostimulatorne oligonukleotide |
| KR20200039025A (ko) | 2013-09-19 | 2020-04-14 | 조에티스 서비시즈 엘엘씨 | 유성 아쥬반트 |
| MX2020011887A (es) | 2018-05-07 | 2021-03-29 | Res Found Dev | Polipéptidos inmunorreactivos. |
| AU2019311181A1 (en) | 2018-07-27 | 2021-02-18 | Research Development Foundation | Chimeric immunogenic polypeptides |
-
2020
- 2020-07-13 PH PH1/2022/550081A patent/PH12022550081A1/en unknown
- 2020-07-13 US US17/626,866 patent/US12624093B2/en active Active
- 2020-07-13 EP EP20751422.5A patent/EP3996741A1/en active Pending
- 2020-07-13 AU AU2020314625A patent/AU2020314625A1/en not_active Abandoned
- 2020-07-13 WO PCT/US2020/041779 patent/WO2021011456A1/en not_active Ceased
- 2020-07-13 CA CA3146842A patent/CA3146842A1/en active Pending
- 2020-07-13 JP JP2022501147A patent/JP2022540197A/ja active Pending
- 2020-07-13 MX MX2022000525A patent/MX2022000525A/es unknown
- 2020-07-13 CN CN202080064004.XA patent/CN114514238A/zh active Pending
- 2020-07-13 BR BR112022000347A patent/BR112022000347A2/pt unknown
-
2022
- 2022-01-12 CL CL2022000086A patent/CL2022000086A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022000347A2 (pt) | 2022-04-12 |
| CL2022000086A1 (es) | 2022-09-30 |
| JP2022540197A (ja) | 2022-09-14 |
| CN114514238A (zh) | 2022-05-17 |
| AU2020314625A1 (en) | 2022-02-03 |
| EP3996741A1 (en) | 2022-05-18 |
| WO2021011456A1 (en) | 2021-01-21 |
| CA3146842A1 (en) | 2021-01-21 |
| PH12022550081A1 (en) | 2023-04-12 |
| US20220356231A1 (en) | 2022-11-10 |
| US12624093B2 (en) | 2026-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019003264A1 (es) | Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas. (divisional solicitud 201703151) | |
| MX2021000193A (es) | Selección de epítopos de vacunas personalizadas contra el cáncer. | |
| MX2023000211A (es) | Composiciones de vacuna que tienen estabilidad e inmunogenicidad mejoradas. | |
| BRPI1013780B8 (pt) | Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica | |
| CL2018000320A1 (es) | Coadyuvantes basados en aceite (divisional de solicitud 201600650) | |
| CR20140436A (es) | Vacuna de combinación contra mycoplasma hyopneumoniae | |
| CL2015001111A1 (es) | Composición coadyuvante que comprende un hidrato de carbono unido al quitosano formando una base de schiff; formulación de vacuna que la comprende; método de elaboración; y uso de la vacuna. | |
| CO7160025A2 (es) | Vacuna de combinación contra pcv/mycoplasma hyopneumoniae | |
| AU2015296298A8 (en) | Flagellin-based agents and uses including effective vaccination | |
| AR089797A1 (es) | Vacunas contra clostridum difficile que comprenden toxinas recombinantes | |
| CO6361948A2 (es) | Uso de antigeno de mycoplasma bovis | |
| MX2016016746A (es) | Composiciones de vacuna con adyuvante dual, preparacion y usos. | |
| BR112015021523A8 (pt) | composição de uma vacina contra a tosse convulsa acelular, e, usos da composição e de antígenos da bordetella pertussis | |
| PE20151588A1 (es) | Vacuna contra el virus del dengue | |
| MX2020004367A (es) | Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan. | |
| CL2016002402A1 (es) | Composiciones inmunológicas que contiene histophilus somni atenuado | |
| BR112015005056A2 (pt) | vacinas de combinação com sorogrupo b meningococcus e d/t/p | |
| BR112019003992A2 (pt) | vacina contra neisseria meningitidis | |
| BR112018069100A2 (pt) | uma vacina combinada contra a infecção por vírus pcv2 e mycoplasma hyopneumoniae | |
| MX2023012390A (es) | Vacunacion con particulas de replicon y adyuvante oleoso. | |
| MX2016001695A (es) | Composiciones inmunogenas de combinacion. | |
| AR099960A1 (es) | Procedimientos y composición farmaceutica para inducir una respuesta inmunitaria | |
| MX2016016080A (es) | Vacunas guiadas por anticuerpos y metodos de uso para generar respuestas imunitarias maduras rapidas. | |
| AR089995A1 (es) | Vacunas de subunidades de rotavirus, metodos de preparacion y uso de las mismas | |
| CL2022000086A1 (es) | Vacunas contra ehrlichia y composiciones inmunogénicas |